Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial

DSpace Repository

Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial

Author: Gallwitz, B.; Rosenstock, J.; Patel, S.; von Eynatten, M.; Hehnke, U.; Mehlburger, L.; Dugi, K. A.; Woerle, H. -J.
Tübinger Autor(en):
Gallwitz, Baptist
Published in: Diabetes Obesity & Metabolism (2015), Bd. 17, H. 3, S. 276-284
Verlagsangabe: Wiley - Blackwell
Language: English
Full text: http://dx.doi.org/10.1111/dom.12419
ISSN: 1462-8902
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)